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Abstract NG108-15 cells were transfected to stably express a haemagglutinin epitope-tagged variant of the long isoform of G#. Clone BST15 
expressed this polypeptide atsimilar levels to the endogenous long isoform of Gs0t. Treatment of clone BST15 with e IP prostanoid receptor agonist 
iloprost resulted in down-regulation f both forms of G,~ with both dose-effect urves to iloprost and time courses of loss of the two forms ofGsc~ 
being indistinguishable. These results demonstrate that the IP prostanoid receptor interacts with and regulates the epitope-tagged variant of G# in 
an equivalent manner to the unmodified protein and indicates that the epitope-tagged polypeptide can be used to analyse mechanisms of receptor 
regulation of cellular G-protein levels. 
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1. Introduction 
Many hormones, neurotransmitters and growth factors exert 
their effects on target cells and tissues by modulating the intra- 
cellular levels of various econd messengers, a process mediated 
via members of a family of guanine nucleotide binding proteins 
(G-proteins) [1]. Sustained exposure of cells or tissues to ag- 
onists which function via G-protein-linked receptors frequently 
results in down-regulation f that receptor, attenuating cellular 
responses to the ligand. Receptors are not the only components 
of this signalling process that are regulated by ligand: the l vels 
of cellular G-proteins are also reduced upon receptor activation 
in many cases [2]. Further, this down-regulation appears to be 
specific to that G-protein with which the receptor interacts [2]. 
Neuroblastomax glioma hybrid, NG108-15, cells express 
endogenously an IP prostanoid receptor, activation of which 
results in stimulation of adenylyl cyclase. Prolonged treatment 
of these cells with iloprost, an agonist at this receptor esults 
in a marked decrease in cellular levels of the cz subunit of G~ 
without altering the levels of any other G-proteins [3-5]. We 
have also recently transfected NG108-15 cells to express the 
human fl2-adrenoceptor and demonstrated that exposure of 
cells of clone fiN22 derived from this transfection to isoprenal- 
ine also results in a specific down-regulation f G~g [6]. In both 
CHO cells transfected to express the muscarinic M1 ace- 
tylcholine receptor [7] and in c~T3-1 cells which express en- 
dogenously the receptor for gonadotrophin releasing hormone 
[8], down-regulation of the phosphoinositidase Cfl-linked 
G-proteins Gq and Gl~ occurs upon sustained exposure to ag- 
onist. In each of these cells the mechanism has been shown to 
be agonist-induced accelerated turnover of the G-proteins ([9] 
and Shah et al., unpublished observations). We have not been 
able to ascertain directly the mechanism of prostanoid and 
fl-adrenoceptor-mediated down-regulation f G/z in NG108-15 
cells and the transfectants derived from them as available 
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anti-Gs0t antisera have poor immunoprecipitation properties. 
As a potential means to address this question herein we have 
transfeeted NGI08-15 cells with an epitope-tagged version of 
the long isoform of Gs~ in which a haemagglutinin epitope from 
the human influenza virus has been incorporated into the poly- 
peptide (HA-G,~(L)) [10]. In the present study we examine the 
ability of agonist occupation of the IP prostanoid receptor to 
interact with and regulate cellular levels of HA-Gs~(L). We 
demonstrate hat the IP prostanoid receptor interacts with HA- 
G,~(L) and that it shows no preference for endogenous G~(L)  
over the epitope-tagged version of the polypeptide. 
2. Materials and methods 
2.1. Generation and isolation of clones of NG108-15 cell variants 
expressing HA-G~g(L) 
NG 108-15 cells were stably co-transfected with plasmid pcDNA 1 ( 10 
gg) containing a eDNA encoding the long isoform of Gsc* in which the 
haemagglutinin epitope (VPDYA) was constructed between amino acid 
residues 76-82 [10] (a kind gift from Drs M.J. Levis and H.R. Bourne, 
University of California at San Francisco, CA, USA) and plasmid 
pBABE hygro (1/.tg) which confers resistance to hygromycin B. Clones 
which were resistant to hygromycin B (200 :tg/ml) were selected and 
expanded. 
2.2. Cell culture 
Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) 
which was supplemented to 5% (v/v) with foetal bovine serum. This 
medium was further supplemented with hypoxanthine, aminopterin, 
thymidine, 100 U/ml of penicillin and I00/ag/ml streptomycin. Trans- 
fectants were routinely grown in medium containing hygromycin B (200 
/tg/ml). 
2.3. Membrane preparation 
Cells were harvested, washed twice in phosphate-buffered saline nd 
pelleted by centrifugation at 500 x g for 10 min on a Beckman TJ-6 
benchtop centrifuge. Membranes were pr pared by homogenizing the 
cell pellet with 20 strokes of a Teflon/glass homogenizer in 10 mM 
Tris-HCl, 0.1 mM EDTA pH 7.5 (buffer A). The resultant supernatant 
was centrifuged at 500 x g for 10 rain in a Beckman L5-50B centrifuge 
with a Ti50 rotor, to remove unbroken cells and nuclei. The supematant 
was further centrifuged at 48,000 x g for 10 rain. The pellet from this 
centrifugation was resuspended i  buffer A and recentrifuged at 
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48,000 x g for 10 min. The resultant pellet was resuspended in an appro- 
priate volume of buffer A, aliquoted and stored at -80°C until use. 
Protein concentration was measured according to the method of Lowry 
et al. [11]. 
2.4. Immunoblotting 
Membranes were resolved by SDS-PAGE (10% (w/v) acrylamide) 
and subsequently immunoblotted with a range of antisera s previously 
described [12]. Antiserum CS, previously characterised in [13], was 
raised in a New Zealand White rabbit after immunization with a glu- 
taraldehyde conjugate of keyhole limpet haemocyanin and a synthetic 
peptide, RMHLRQYELL, which corresponds to the C-terminal de 
capeptide common to all isoforms of G,~. This equence is also pre- 
served in HA-G,~t(L). Monoclonal antibody 12CA5 which identifies a 
nonapeptide sequence (YPYDVPDYA) derived from the haemag- 
glutinin protein of human influenza virus, was purchased from 
Boehringer Mannheim. I munoblots were quantitated using a Bio- 
Rad GS-670 Imaging Densitometer linked to an Apple Macintosh 
Quadra 800 microcomputer. 
3. Results 
NG108-15 cells were co-transfected with a cDNA encoding 
the long isoform of G~,  the stimulatory G-protein of the ade- 
nylyl cyclase cascade, into which a five amino acid sequence 
corresponding to an epitope derived from the haemagglutinin 
protein of influenza virus had been engineered between residues 
76-82 [10] in plasmid pcDNA1 and the plasmid pBABE hygro 
to allow for selection based on resistance to hygromycin B. 
Resistant colonies were selected and expanded. Membranes 
were prepared from the clones, resolved using SDS-PAGE and 
immunoblotted with antiserum CS, an antipeptide antiserum 
raised against he C-terminal decapeptide common to all splice 
variants of G,~z. Clone BST15, expressed an immunoreactive 
doublet (Fig. 1, panel A). The band migrating more rapidly 
through the gel comigrated with the 45 kDa (long) isoform of 
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Fig. 1. Confirmation of expression of HA-G,~t(L) in BST15 cells. Mem- 
branes (25 pg) prepared from untransfected NG108-15 cells (1) or 
BST15 cells (2) were resolved on SDS-PAGE (10% (w/v) aerylamide) 
and immunoblotted with either the G/z antiserum CS (1 : 500 dilution) 
(panel A) or the HA epitope-tag antibody 12CA5 (1:400 dilution) 
(panel B). 
HA-Gs(X(L) 
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Fig. 2. The IP prostanoid receptor isable to interact with and down- 
regulate HA-G,~(L) in BST15 cells. Membranes (25 pg) prepared from 
NG108-15 cells (1), untreated BST15 cells (2) and iloprost-treated (1 
pM, 16 h) BST15 cells (3) were resolved on SDS-PAGE (10% (w/v) 
acrylamide) and immunoblotted with antiserum 12CA5 (1:400 dilu- 
tion) to detect HA-G,~(L). Iloprost reatment caused a substantial 
reduction i  levels of immunodetectable HA-G,~L) (see section 3 for 
details). 
G~ endogenously expressed by the parental cells whilst the less 
rapidly migrating band did not comigrate with G,~ im- 
munorcactivity in the parental cells and was presumed to be the 
epitopc-tagged version of this polypeptide, HA-G/~(L) (Fig. 1, 
panel A). Immunoblot analysis of these membranes with anti- 
serum 12CA5, which specifically recognises theengineered epi- 
tope tag region, confirmed the upper immunoreactive species 
to be HA-Gs~(L) and its expression i  BST15 cells but not in 
parental NGI08-15 cells (Fig. 1, panel B). Comparison of den- 
sitometric analyses of such immunoblots revealed that BST15 
cells expressed HA-G,~(L) at a level of some 59.5 + 8.8% 
(mean + S.E.M.; n = 7) of the endogenous G,~(L) in these cells. 
As the parental cells express G,0~(L) at some 9.6 pmol/mg of 
membrane protein [5] then the levels of HA-Gs~(L) are some 
5.7 pmol/mg membrane protein. 
To determine whether HA-G,~(L) was able to interact with 
the IP prostanoid receptor, BST15 cells were incubated in the 
presence of the IP prostanoid agonist iloprost (1 pM, 16 h), 
which has been shown previously to cause a marked decrease 
in the cellular levels of Gs~(L) without altering the levels of any 
other G-protein ~ subunits [3-5]. Immunoblot analysis of mem- 
branes prepared from untreated and iloprost-treated c ils with 
either antiserum CS (see later) or antiserum 12CA5 (Fig. 2) 
revealed that iloprost reatment resulted in a reduction in the 
levels of both Gs~(L) and HA-G~(L).  Densitometric s anning 
of a number of these immunoblots showed that the levels of 
G~t(L) were reduced to 45.1% + 17.2 (mean + S.E.M.; n = 5) 
of the levels observed in membranes from untreated cells. Sim- 
ilarly the levels of HA-G,~(L) were reduced to 48.1% _+ 14.9 
(mean _+ S.E.M.; n = 5) of control levels in iloprost-treated 
cells. 
Treatment of BST15 cells with different concentration of 
iloprost for 16 h followed by immunoblotting with antiserum 
CS indicated that half-maximal decrease in the levels of both 
HA-G,~t(L) and G,~(L) was obtained with approximately 1 nM 
agonist (Fig. 3). Time courses of iloprost treatment (1 gM) 
indicated that half-maximal down-regulation was achieved 
within 1-2 h for both polypeptides and that new steady-state 
levels were produced within approximately 8 h (Fig. 4). 
4. Discussion 
Agonist-mediated down-regulation f G-protein c~ subunits 
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Fig. 3. Dose--response curves for iloprost-induced decrease in the cellu- 
lax level of HA-G,tz(L) and G~t(L) in clone BST15. Immunological 
detection of HA-G,e.(L) and G,¢(L) in membranes of BST15 clones in 
(1) untreated cells or after treatment with iloprost for 16h at (2) 1 pM, 
(3) 100 nM, (4) 10 nM, (5) 1 nM, (6) 100 pM, (7) 10 pM, (8) 1 pM. 
Membranes (25/zg) prepared from these cells were resolved on SDS- 
PAGE (10% (w/v) acrylamide) andimmunoblotted with antiserum CS 
(1 : 500 dilution). 
has been observed for members of each of the Gs, G i and Gq 
families of G-proteins [2]. In CHO cells transfected to express 
the human M1 muscarinic acetylcholine receptor, incubation 
with the agonist carbachol resulted in a reduction in the total 
cellular levels of Gq/Gll, the G-proteins that interact with this 
receptor [7]. Further, Mitchell et al. [9] were able to demon- 
strate that agonist reatment did not substantially alter mRNA 
levels of either Gq= or Gu= but did show that the half life of a 
substantial proportion of the total cellular levels of Gq/GI1 was 
reduced from 18 h to 2.5 h upon addition of carbachol [9]. Thus, 
the observed reduction in the levels of the activated G-protein 
was primarily a consequence of agonist enhancement of turn- 
over of the polypeptide. 
Maintained agonist occupation of the IP prostanoid receptor 
of NG108-15 cells results in a specific down-regulation f G,~t 
[3-5]. This also occurs without substantial lterations in levels 
of G,~z mRNA levels [3] and may well also reflect accelerated 
protein degradation. However, the antisera we have generated 
(and those from a number of other workers) to Gs~t are ineffi- 
cient in immunoprecipitation assays (see [10] for discussion) 
and this restricts the possibility of analysing turnover of the 
protein directly. Levis and Bourne [10] have constructed an 
epitope tagged variant of G~(L) (HA-G~(L)) in which the 
sequence VPDYA was engineered into the amino acid sequence 
derived from exon 3, the region which is lacking in the short 
isoforms of G~cz. As the bulk of evidence indicates that long and 
short isoforms of G~z show little functional difference then it 
was anticipated that alterations in this region might not inter- 
fere with the function of the epitope tagged polypeptide [10]. 
To some extent this has been confirmed [10] but in studies 
which have been designed to analyse the role of post-transla- 
tional palmitoylation i the membrane association of G~cz very 
different results have been obtained in studies using the epitope 
tagged form of HA-G/z(L) [14] from those using the unmodi- 
fled sequence [15,16]. While other explanations, such as the cell 
lines used, may contribute to these observed ifferences they 
clearly indicate that considerable analysis must be performed 
to ensure that HA-Gs~t(L) is suitable for any envisaged set of 
studies, particularly in this case as agonists timulate depalmi- 
toylation of Gscz [17-19] and this may be an early step in 
agonist-induced down-regulation f the polypeptide. 
Thus, in the present study we have stably transfected NG 108- 
15 derived cells to express HA-G/z(L) and subsequently com- 
pared in parallel the ability of IP prostanoid receptor activation 
to regulate both endogenous Gs~z(L) and the introduced HA- 
G,cz(L). Clone BST-15 was selected for detailed analysis as it 
expressed relatively similar levels of G~t(L) and HA-G~g(L) 
(Fig. 1). We were fortunate in these studies that HA-Gs~z(L) 
migrates in SDS-PAGE somewhat more slowly than G/z(L) 
(Figs. I and 3) which allowed for easy concurrent detection and 
analysis of the two polypeptides. 
Treatment of BST15 cells with iloprost not only resulted in 
a substantial decrease in the levels of endogenous Gs~(L) but 
also in the levels of HA-G~cz(L), indicating that the IP pro- 
stanoid receptor was able to interact with the epitope-tagged 
G-protein (Fig. 2). Further, the degree of receptor-G-protein 
interaction was similar for G~ct(L) and HA-G~ct(L) as assessed 
by the similar agonist concentrations eeded to achieve half- 
maximal G-protein down-regulation (Fig. 3). Agonist-pro- 
moted removal of both Gs~t(L) and HA-Gs~(L) from the cell 
was a rapid process with half-maximal loss for both forms 
occurring within approximately 1-2 h (Fig. 4). 
The demonstration that HA-Gs~z(L) levels are regulated in a 
manner indistinguishable from the endogenously expressed 
G/z(L) indicates that this construct may be used to analyse in 
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Fig. 4. Concurrent down-regulation of HA-G~t(L) and Gsct(L) by 
iloprost in clone BSTI 5. After treatment with 1/zM iloprost for various 
times, the levels of immunologically detected Gs~t(L) and HA-G,~t(L) 
in membranes from BST15 clones were assessed. Membranes (25 pg) 
were resolved onSDS-PAGE (10% (w/v) acrylamide) and immunoblot- 
ted with antiserum CS (1 : 500 dilution). A series of such immunoblots 
were subjected to quantitation by densitometric scanning. Levels of 
G,~t(L) (open symbols) and HA-G,~t(L) (closed symbols) are presented 
as a % _+ S.E.M. of those from untreated cells, n = 6.Apart from the 
4 h time point the data did not display statistically significant differ- 
ences between the extent of G,~t(L) and HA-Gsct(L) down-regulation. 
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detail the mechanisms of G-protein loss. The use of antisera 
directed against epitope-tagged G-proteins will potentially also 
be useful in systems where there are no G-protein antisera 
available. 
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